Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 8 to 17

PPF3 vs placebo in children and teens with autism

Official title: A Randomized Placebo-Controlled TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS- The TRICERATOPS Study

Run by Holland Bloorview Kids Rehabilitation Hospital · NCT07893964 · Data updated 2026-11-12

This trial tests whether PPF3 helps improve symptoms in children and adolescents with autism compared to placebo.

Quick facts

PhasePhase 2
Study typeInterventional
Ages8 Years to 17 Years
SexAll
Enrollment100 (estimated)
SponsorHolland Bloorview Kids Rehabilitation Hospital
Academic / other
Locations4 sites (Hamilton, Ontario and 3 other locations)
StatusRecruiting
StartedOctober 2026
Main results expectedOctober 2028
Study endsOctober 2028
Registry record updatedOctober 29, 2026
Trial IDNCT07893964 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are outpatients aged 8-17 with ASD (DSM-5 confirmed, ADOS-2 supported), weight ≥ 30 kg, previously in the POND cohort, and stable on any current medications with consent for birth control for sexually active females of childbearing potential.

Probably not a fit

Patients not benefiting could include those who do not respond to PPF3 or who experience adverse effects that outweigh potential benefits.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 randomized, placebo-controlled trial examining the effect of PPF3 in individuals aged 8 to 17 with autism spectrum disorder who weigh at least 30 kg and have previously participated in the POND cohort. Participants are outpatients and must meet DSM-5 criteria for ASD, with confirmation by ADOS-2, and have a CGI-S score of at least 4. Stable concomitant medications are allowed if unchanged for the prior month (six weeks for fluoxetine). The study is conducted across multiple Ontario sites, with Holland Bloorview Kids Rehabilitation Hospital as lead sponsor and support from the Ontario Brain Institute and Purposeful.

Why it matters

Potential benefit: If successful, participants may experience improvements in symptoms or functioning related to autism.

How similar studies have gone: Previous studies in related neurodevelopmental targets have shown mixed results; this trial tests a novel intervention in a pediatric ASD population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Outpatients 8-17 years of age, inclusive, with a weight ≥ 30 kg.
* Already have participated in POND cohort
* Females of childbearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug.
* Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria (American Psychiatric Association, 2013) for ASD. Diagnosis will be supported by the ADOS-2. Diagnostic and Statistical Manual (DSM-5) criteria will be established by a clinician with expertise with individuals with ASD.
* Have a Clinical Global Impression-Severity (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill)
* If already receiving interventions, must meet the following criteria:
* If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening (6 weeks for Fluoxetine) and will not electively modify ongoing medications for the study duration.

  b. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions.
* Have a negative pregnancy test at screening for patients who have experienced menarche
* Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Qualified Investigator.

Ability to obtain written informed consent from the participant, if developmentally appropriate. If a participant does not have the capacity to consent, ability to obtain assent (if developmentally appropriate), as well as written informed consent from their parent(s)/legal guardian.

Exclusion Criteria:

Please contact the site for details

Where it's running

  • Holland Bloorview Kids Rehabilitation Hospital
    Toronto, Ontario, Canada
    Recruiting
  • McMaster University
    Hamilton, Ontario, Canada
    Not yet recruiting
  • Queen's University
    Kingston, Ontario, Canada
    Not yet recruiting
  • London Health Sciences Centre
    London, Ontario, Canada
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.